EDAP TMS S.A., doing business as FocalTherics, operates as a medical technology company that develops, manufactures, markets, and sells non-invasive therapeutic ultrasound and energy-based medical devices in Asia, France, the United States, and internationally. The company develops, manufactures, markets, and distributes non-invasive robotic HIFU systems for urology-related and other indications. It also offers Focal One, a HIFU robotic system to treat patients diagnosed with prostate cancer, as well as disposables, and leasing and treatment related services; and maintenance services. In addition, the company manufactures and markets lithotripter for the treatment of urinary tract stones; and provides disposables, replacement parts, and services for lithotripters; and sells spare parts and disposables, such as electrodes. Further, it markets, distributes, and services lasers, micro-ultrasound systems, and other medical products from third parties, as well as leases devices; sells disposables and spare parts; and offers maintenance services. The company markets and sells its products through its direct marketing, sales channels, and third-party distributors and agents. The company serves academic, public, and private hospitals, as well as clinics. The company has a strategic collaboration with Telix Pharmaceuticals Limited to develop clinical workflows combining PSMA PET imaging and Focal One Robotic HIFU for prostate cancer. EDAP TMS S.A. was incorporated in 1979 and is headquartered in Vaulx-en-Velin, France.…
European Equities Traded in the US as American Depositary Receipts Decline in Thursday Trading
EDAP TMS (NASDAQ: FOCL) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Distribution industry, part of the Healthcare sector, and reports about 289 employees.
The shares were at 2.610 USD on 20 November 2026, up 29.2% over 52 weeks. Its 52-week range is 1.920 USD to 6.400 USD: the price is 59.2% below the high and 35.9% above the low.
Its market capitalisation is 123.25M USD.
EDAP TMS reports return on equity of -150.7%, an operating margin of -35.0% and revenue up 25.5% year over year.
It holds more cash than debt, a net cash position of 18.68M USD. Its Piotroski F-score is 4 out of 9, an average reading of its financial health. 5 analysts cover the stock, with an average rating of Buy; their mean price target of 8.300 USD is 218.0% above the current price. The next earnings report is expected on 24 March 2027.